SEC Form 4 · accession 0001209191-17-067564
SteadyMed Ltd. · STDY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jonathan Rigby
Officer — President and CEO · Director
Period of report
Dec 28, 2017
Accepted (ET)
Dec 28, 2017 · 3:31 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001619087
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1,F2 | Dec 28, 2017 | A | 83,210 | $0.00 | A | 83,210 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $3.65 | Dec 28, 2017 | A | 163,394 | A | — | Dec 28, 2027 | Ordinary Shares | 163,394 | 163,394 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of SteadyMed Ltd. ordinary shares.
- F2The restricted stock units ("RSUs")are 50% time-based and 50% performance based grants. 50% of the RSUs shall vest on June 30, 2018 and 50% shall vest upon approval by the FDA of the New Drug Application for Trevyent.
- F31/3rd of the Option Shares shall vest on the first anniversary of the grant date. Thereafter, the remaining balance of the Option Shares shall vest in a series of 8 equal consecutive quarterly installments until fully vested.